Log in

NASDAQ:SRPTSarepta Therapeutics News Headlines

$162.75
-2.93 (-1.77 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$162.52
Now: $162.75
$169.17
50-Day Range
$141.25
MA: $156.18
$171.70
52-Week Range
$72.05
Now: $162.75
$172.70
Volume539,637 shs
Average Volume1.05 million shs
Market Capitalization$12.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.92

Headlines

Sarepta Therapeutics (NASDAQ SRPT) News Headlines

Source:
DateHeadline
Sarepta Therapeutics inks deal for imlifidase for use in muscular dystrophiesSarepta Therapeutics inks deal for imlifidase for use in muscular dystrophies
seekingalpha.com - July 2 at 12:30 PM
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for ImlifidaseSarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
finance.yahoo.com - July 2 at 7:25 AM
Sarepta Therapeutics (NASDAQ:SRPT) Cut to "Buy" at BidaskClubSarepta Therapeutics (NASDAQ:SRPT) Cut to "Buy" at BidaskClub
www.marketbeat.com - July 2 at 3:56 AM
Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select IndicationsHansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics to Develop and Promote Imlifidase as Pre-treatment Ahead of Gene Therapy in Select Indications
www.benzinga.com - July 2 at 2:35 AM
Sarepta Therapeutics CFO bids adieuSarepta Therapeutics CFO bids adieu
seekingalpha.com - June 30 at 12:30 PM
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business OfficerSarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
finance.yahoo.com - June 30 at 12:30 PM
 Analysts Anticipate Sarepta Therapeutics Inc (NASDAQ:SRPT) Will Post Quarterly Sales of $116.62 Million Analysts Anticipate Sarepta Therapeutics Inc (NASDAQ:SRPT) Will Post Quarterly Sales of $116.62 Million
www.americanbankingnews.com - June 30 at 5:07 AM
Sarepta Completes Rolling NDA Submission for New DMD TherapySarepta Completes Rolling NDA Submission for New DMD Therapy
finance.yahoo.com - June 29 at 3:01 PM
Sarepta Therapeutics Inc (NASDAQ:SRPT) Expected to Post Earnings of -$1.72 Per ShareSarepta Therapeutics Inc (NASDAQ:SRPT) Expected to Post Earnings of -$1.72 Per Share
www.americanbankingnews.com - June 28 at 1:10 AM
Sarepta finalizes NDA submission for casimersenSarepta finalizes NDA submission for casimersen
seekingalpha.com - June 26 at 1:34 PM
Sarepta finalizes U.S. application for DMD med casimersenSarepta finalizes U.S. application for DMD med casimersen
seekingalpha.com - June 26 at 1:34 PM
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
finance.yahoo.com - June 26 at 1:34 PM
Sarepta Therapeutics Inc (NASDAQ:SRPT) Given Average Rating of "Buy" by BrokeragesSarepta Therapeutics Inc (NASDAQ:SRPT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 12:33 PM
Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene TherapySelecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapy
seekingalpha.com - June 23 at 3:43 PM
Sarepta Inks Agreement With Codiak to Develop Gene TherapiesSarepta Inks Agreement With Codiak to Develop Gene Therapies
finance.yahoo.com - June 23 at 3:43 PM
Sarepta, Codiak BioSciences Team Up For Neuromuscular Disease TargetingSarepta, Codiak BioSciences Team Up For Neuromuscular Disease Targeting
finance.yahoo.com - June 23 at 10:42 AM
Sarepta Therapeutics Inc (NASDAQ:SRPT) EVP Sells $17,963,247.36 in StockSarepta Therapeutics Inc (NASDAQ:SRPT) EVP Sells $17,963,247.36 in Stock
www.marketbeat.com - June 22 at 11:19 PM
Sarepta teams up with Codiak BioSciences in neuromuscular diseasesSarepta teams up with Codiak BioSciences in neuromuscular diseases
seekingalpha.com - June 22 at 6:19 PM
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $190.00 by Analysts at JPMorgan Chase & Co.Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $190.00 by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - June 22 at 12:17 PM
Sarepta Therapeutics (NASDAQ:SRPT) Sets New 52-Week High Following Analyst UpgradeSarepta Therapeutics (NASDAQ:SRPT) Sets New 52-Week High Following Analyst Upgrade
www.marketbeat.com - June 22 at 11:28 AM
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare DiseasesSarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
www.benzinga.com - June 22 at 8:18 AM
How Sarepta and Selecta Bio Are Taking the Fight to DMDHow Sarepta and Selecta Bio Are Taking the Fight to DMD
247wallst.com - June 18 at 1:29 PM
Sarepta closes deal for Selecta platform for use in muscular dystrophiesSarepta closes deal for Selecta platform for use in muscular dystrophies
seekingalpha.com - June 18 at 1:29 PM
Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from HC WainwrightSarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from HC Wainwright
www.marketbeat.com - June 17 at 6:10 AM
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - June 16 at 12:45 PM
Sareptas Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety HurdleSarepta's Gene Therapy for Duchenne Muscular Dystrophy Clears a Major Safety Hurdle
finance.yahoo.com - June 15 at 8:04 PM
Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Bank of AmericaSarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Bank of America
www.americanbankingnews.com - June 11 at 7:31 AM
Sareptas Gene Therapy Promising in Muscular Dystrophy StudySarepta's Gene Therapy Promising in Muscular Dystrophy Study
finance.yahoo.com - June 9 at 3:36 PM
Sarepta Therapeutics Shares March Higher, Can It Continue?Sarepta Therapeutics' Shares March Higher, Can It Continue?
finance.yahoo.com - June 9 at 9:48 AM
Notable Monday Option Activity: SRPT, DOW, MTDRNotable Monday Option Activity: SRPT, DOW, MTDR
www.nasdaq.com - June 8 at 6:58 PM
New data hints at payoff from Sareptas $600M gene therapy investmentNew data hints at payoff from Sarepta's $600M gene therapy investment
www.bizjournals.com - June 8 at 6:58 PM
Sarepta Beats Its Own Gene Therapy Expectations — And Shares SurgeSarepta Beats Its Own Gene Therapy Expectations — And Shares Surge
finance.yahoo.com - June 8 at 6:58 PM
What does the future hold for the Sarepta Therapeutics Inc share price?What does the future hold for the Sarepta Therapeutics Inc share price?
uk.finance.yahoo.com - June 8 at 1:53 PM
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2ESarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
finance.yahoo.com - June 8 at 1:52 PM
Sarepta Therapeutics Pops As Gene Therapy Study Tops ExpectationsSarepta Therapeutics Pops As Gene Therapy Study Tops Expectations
finance.yahoo.com - June 8 at 1:52 PM
Sarepta Gene Therapy Win Helps to Validate Broader PlatformSarepta Gene Therapy Win Helps to Validate Broader Platform
finance.yahoo.com - June 8 at 1:52 PM
Sarepta to release data on gene therapy for rare type of muscular dystrophySarepta to release data on gene therapy for rare type of muscular dystrophy
seekingalpha.com - June 5 at 7:16 PM
Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-SarcoglycanopathySarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
finance.yahoo.com - June 5 at 7:16 PM
Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?Why Is Sarepta Therapeutics (SRPT) Up 17.3% Since Last Earnings Report?
finance.yahoo.com - June 5 at 2:16 PM
Sarepta Therapeutics to Present at Upcoming Investor ConferencesSarepta Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - June 2 at 6:54 PM
Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?Is Sarepta Therapeutics (SRPT) Outperforming Other Medical Stocks This Year?
finance.yahoo.com - May 28 at 1:59 PM
Pfizers Data Release Shows That It Still Is Light-Years Behind Sarepta In DMDPfizer's Data Release Shows That It Still Is Light-Years Behind Sarepta In DMD
seekingalpha.com - May 21 at 8:39 AM
Sarepta Surges on Rival Pfizers DMD Gene Therapy Study DataSarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
www.nasdaq.com - May 18 at 3:07 PM
Pfizer Reports Efficacy & Safety Data on DMD Gene TherapyPfizer Reports Efficacy & Safety Data on DMD Gene Therapy
finance.yahoo.com - May 18 at 3:07 PM
Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study DataSarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data
finance.yahoo.com - May 18 at 3:07 PM
Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta TherapeuticsPfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics
www.fool.com - May 15 at 4:06 PM
When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit?When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit?
finance.yahoo.com - May 14 at 2:16 PM
Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare ConferenceSarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
www.benzinga.com - May 12 at 5:12 PM
Sarepta Investors Buckle Up for Pfizer’s DMD Gene Therapy UpdateSarepta Investors Buckle Up for Pfizer’s DMD Gene Therapy Update
finance.yahoo.com - May 12 at 5:12 PM
Novartis, Sarepta partner with new George Church gene therapy startupNovartis, Sarepta partner with new George Church gene therapy startup
www.bizjournals.com - May 11 at 8:00 AM
This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.